Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.
暂无分享,去创建一个
[1] R. Chaisson,et al. Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.
[2] M. French,et al. Hepatitis C virus‐associated hepatitis following treatment of HIV‐infected patients with HIV protease inhibitors: an immune restoration disease? , 1998, AIDS.
[3] J. Peña,et al. Acute hepatitis in HIV-infected patients during ritonavir treatment. , 1998, AIDS.
[4] Gill Mj. Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. NV15182 Study Team. , 1998 .
[5] V. Soriano,et al. Hepatotoxicity after introduction of highly active antiretroviral therapy. , 1998, AIDS.
[6] A. Albanese,et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. , 1998, American journal of respiratory and critical care medicine.
[7] D. Ho,et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. , 1998, The Journal of infectious diseases.
[8] David A. Cooper,et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.
[9] C. Rouzioux,et al. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[11] B. Hirschel,et al. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. , 1998, The Journal of infectious diseases.
[12] Calvin Cohen,et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease , 1998, The Lancet.
[13] L. Miwa,et al. Value of epidemiologic studies in determining the true incidence of adverse events. The nonsteroidal anti-inflammatory drug story. , 1997, Archives of internal medicine.
[14] E A Emini,et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. , 1997, The New England journal of medicine.
[15] J. Matsuda,et al. Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir , 1997, The Lancet.
[16] F. Hecht,et al. Protease inhibitors in the homeless. , 1997, JAMA.
[17] D. Margolis,et al. Severe hepatitis in three AIDS patients treated with indinavir , 1997, The Lancet.
[18] S. Pol,et al. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] S. Hammer,et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. , 1996, The New England journal of medicine.
[20] J. Darbyshire,et al. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.
[21] R. Chaisson,et al. Adverse events from drug therapy for human immunodeficiency virus disease. , 1996, The American journal of medicine.
[22] T. Merigan,et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. , 1996, The New England journal of medicine.
[23] A. D. Rodrigues,et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[24] D. Ho,et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. , 1995, The New England journal of medicine.
[25] L. M. Lehman,et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. , 1995, The New England journal of medicine.
[26] R. Chaisson,et al. Race, sex, drug use, and progression of human immunodeficiency virus disease. , 1995, The New England journal of medicine.
[27] R. Chaisson,et al. Racial differences in the use of drug therapy for HIV disease in an urban community. , 1994, The New England journal of medicine.
[28] S. Safrin,et al. Interactions and toxicities of drugs used in patients with AIDS. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] D. Cooper,et al. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. , 1991, The Journal of infectious diseases.
[30] R. Perrillo,et al. Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. , 1986, Annals of internal medicine.
[31] Eyton,et al. A CONTROLLED TRIAL OF TWO NUCLEOSIDE ANALOGUES PLUS INDINAVIR IN PERSONS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION AND CD4 CELL COUNTS OF 200 PER CUBIC MILLIMETER OR LESS , 2000 .
[32] T. Ferraro,et al. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. , 1998, AIDS.
[33] M. Gill. Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. NV15182 Study Team. , 1998, AIDS.
[34] F. Wit,et al. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. , 1997, Lancet.